Aurhance Capital Management to Launch First Cryptocurrency ETF in February 2026
In response to this accelerating momentum, Aurhance Capital Management, a global asset management firm headquartered in a leading international financial center, announced today that it will launch its inaugural cryptocurrency ETF in February 2026.
The ETF is designed to offer institutional and qualified investors a regulated, structured, and transparently monitored vehicle to access the digital asset market. With an initial offering size of USD 1 billion, the fund reflects Aurhance's strategic commitment to establishing it as a flagship product within its portfolio.
The ETF will track the performance of a diversified basket of major cryptocurrencies, combined with Aurhance's proprietary multi-factor risk control system and dynamic rebalancing methodology. Portfolio holdings will be disclosed daily, and all assets will be safeguarded by an independent third-party custodian.
'Digital assets are becoming integral to global portfolio construction,' said the firm's CEO. 'Yet institutional investors continue to demand robust risk management and strong regulatory oversight. This ETF offers a mature and structured entry point combining compliance rigor with technology-driven investment logic.'
Aurhance noted that the February 2026 launch date follows an extensive evaluation of global market and regulatory conditions. Recent developments in the U.S., Europe, and parts of Asia have accelerated the approval process for digital asset ETFs, laying the groundwork for more stable cross-border investment frameworks.
The firm believes institutional demand for compliant, transparent access to digital assets is growing especially among first-time allocators. Industry analysts agree, noting that cryptocurrency ETFs reduce operational friction and bring digital assets closer to the standards of traditional finance. 'Digital assets are evolving from fringe alternatives to core portfolio components,' said an independent research analyst. 'Regulated ETFs offer liquidity, pricing transparency, and compliance key prerequisites for institutional participation.'
Founded in 2019, Aurhance Capital Management specializes in quantitative strategies, global asset allocation, and technology-led investing. The firm focuses on high-growth sectors such as artificial intelligence, quantum computing, life sciences, renewable energy, and sustainable technologies leveraging advanced analytics to identify long-term structural opportunities.
The new cryptocurrency ETF will further expand Aurhance's multi-asset investment platform, complementing its suite of quantitative and innovation-focused growth funds. The firm is also actively developing next-generation investment products linked to emerging technologies, in line with its mission to deliver multi-dimensional growth strategies aligned with global transformation trends.
'Our goal isn't just to capture returns , it's to design resilient, future-proof investment structures,' the CEO added. 'With this ETF, we're enabling clients to access the digital asset economy with the confidence and discipline expected of institutional finance.'
Contact Info:
Name: Robyn william Conley
Email: Send Email
Organization: Aurhance Capital Management Inc
Website: https://www.ahcym.com
Disclaimer:
This press release is for informational purposes only. Information verification has been done to the best of our ability. Still, due to the speculative nature of the blockchain (cryptocurrency, NFT, mining, etc.) sector as a whole, complete accuracy cannot always be guaranteed.
You are advised to conduct your own research and exercise caution. Investments in these fields are inherently risky and should be approached with due diligence.
Release ID: 89167169
If there are any deficiencies, discrepancies, or concerns regarding the information presented in this press release, we kindly request that you promptly inform us by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team is committed to addressing any identified issues within 8 hours to guarantee the delivery of accurate and reliable content to our esteemed readers.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Bitcoin price hits record high above $123,500 amid crypto rally
Bitcoin (BTC-USD) surged to a new all-time high above $123,500 (£90,984) in early Thursday trading, extending a week-long rally that has lifted the broader cryptocurrency market. Bitcoin briefly traded at $123,512 before easing back to around $121,700. The world's biggest cryptocurrency is now up more than 6% over the past week, breaking through its previous July peak of just over $120,000. Read more: Crypto live prices 'Bitcoin's latest rally reflects the blurring lines between crypto and traditional assets, happening faster than institutional adoption timelines predicted,' VOOI CEO and co-founder Will K said. 'While ETFs brought institutions into bitcoin, retail traders are returning to evolved decentralised platforms that have shed their clunky origins.' Ethereum (ETH-USD) outpaced bitcoin in percentage gains, jumping 28% over the past seven days to trade above $4,742, inching closer to its November 2021 record of $4,865. 'Ethereum's rally is being driven by strong ETF inflows, institutional accumulation, and a favourable macro backdrop after softer CPI data boosted rate-cut expectations,' Bitfinex head of derivatives Jag Kooner said. 'Traders have rotated back into risk, with bitcoin and ether both seeing renewed long positioning, while options data shows low implied volatility and a build-up in open interest, signalling that markets expect a sharp move ahead but are hedging downside risk.' The total cryptocurrency market capitalisation now stands at $4.23tn, up 1.9% on Thursday, according to CoinMarketCap data. The crypto rally comes as US equities closed higher on Wednesday, with the S&P 500 (^GSPC) and Nasdaq (^IXIC) hitting fresh record highs this week. The broader risk-on sentiment has spilled over into digital assets. Read more: One US law reshaped crypto overnight. Ripple explains why Bitcoin's surge has been underpinned by a friendlier regulatory climate in Washington. Earlier this month, US president Donald Trump signed an executive order directing federal banking regulators to scrap 'reputational risk' as a factor in supervision, a designation that had often led banks to cut ties with lawful crypto firms. The move, part of a broader rollback of restrictions critics dubbed 'Operation Choke Point 2.0,' has been coupled with the disbanding of the Justice Department's National Crypto Enforcement Team and new legislation to establish a federal framework for stablecoins. Industry leaders have said the shift is clearing a path for greater institutional participation in digital assets, adding momentum to bitcoin's rally. Read more: Why pension funds are buying bitcoin What is a spot bitcoin ETF and why has it sparked a crypto rally? How AI could change the internet
Yahoo
2 hours ago
- Yahoo
Kuros Biosciences Reports First Half of 2025 Results
Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 2024: USD 35.7 million) Direct MagnetOs™ sales increased by 77% to USD 62.7 million in H1 2025 (H1 2024: USD 35.4 million) The Group achieved its first-ever operating profit, reaching USD 3.5 million, compared to an operating loss of USD (0.2) million in H1 2024 Total Group EBITDA reached USD 5.1 million in H1 2025 (H1 2024: USD 0.8 million) and total Group adjusted EBITDA* amounted to USD 7.8 million in H1 2025, equaling a margin of 12.3% (H1 2024: USD 4.5 million at 12.6%). After amortization, depreciation, the net finance result, income tax and the profit/loss from discontinued operations, the Group reported a net loss of USD (2.0) million in H1 2025 (H1 2024: USD (0.2) million) Cash position remains strong while funding strategic growth initiatives and investing in working capital, with cash and cash equivalents totaling USD 18.4 million as of June 30, 2025 (December 31, 2024: USD 19.8 million) Reporting currency changed from CHF to USD to align with the Group's primary market and operational footprint in the U.S. The Group continues to expect sales growth of at least 60% in 2025 and anticipates sales of between USD 220 million and USD 250 million by 2027 Schlieren (Zurich), Switzerland, August 14, 2025 – Kuros Biosciences ('Kuros' or the 'Company') a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2025, demonstrating continued momentum in growth, broader market reach, and progress on key strategic priorities. Total group revenue reached USD 63.5 million, marking a growth of 78% compared to H1 2024. Revenue from Direct MagnetOs product sales increased 77% year-on-year to USD 62.7 million (H1 2024: USD 35.4 million). The company achieved an operating profit of USD 3.5 million in the first half of 2025, marking its first positive operating result, up from an operating loss of USD (0.2) million in H1 2024. The Group achieved an EBITDA of USD 5.1 million in H1 2025, increasing from USD 0.8 million in H1 2024. Adjusted EBITDA* totaled at USD 7.8 million, up from USD 4.5 million in H1 2024. This represents an adjusted EBITDA* margin of 12.3%. The Group does not expect a material impact from U.S. tariffs in 2025. Finally, the reporting currency was changed from Swiss francs (CHF) to U.S. dollars (USD) to reflect the Group's primary market and business activities. Chris Fair, Chief Executive Officer of Kuros Biosciences, said: 'We recorded exceptional company revenue growth of 78%, marking a pivotal phase of scale and impact for Kuros. An outstanding accomplishment is that the group has for the first time ever recorded an operating profit. With FDA clearance and U.S. launch of MagnetOs MIS, accelerating growth in extremities, and entry into new international markets, we continue to deliver with innovation, precision, and purpose. The strategic alliance with Medtronic is expanding our reach across U.S. spine markets, while our new Atlanta headquarters will enable domestic production and an immersive educational experience for surgeons, partners, and investors. Backed by strong financial performance, an experienced and diverse board, and momentum across all segments, we are well-positioned to sustain growth and create long-term value for patients, providers, and shareholders globally.' Commercial, Operational & Regulatory Highlights Medtronic U.S. Spine Partnership Gains Traction – In January 2025, Kuros finalized a five-year exclusive strategic sales agent agreement with the Medtronic spinal division for MagnetOs in mutually agreed upon U.S. sales territories. The partnership, which evolved from a successful pilot, is accelerating commercial access and hospital entry across key geographies, serving as a major force multiplier for Kuros' U.S. growth. FDA Clearance & First Cases with MagnetOs MIS Delivery System – Kuros has received FDA 510(k) clearance for its MagnetOs MIS Delivery System, a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery (MIS) in spine procedures. The system enables three times faster graft placement compared to traditional funnel-based methods, combining precise delivery with compelling Level I clinical data.1,2 Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. 'MagnetOs MIS delivered smooth, precise graft placement in a typically challenging MIS TLIF case – no preparation, no thawing, just immediate delivery and efficiency. It pairs streamlined handling with compelling clinical data, making it a meaningful advancement for surgeons who value both efficiency and biologically robust healing,' said Dr. Park. Continued Momentum in Extremities Market – With an established team dedicated to the extremities segment, Kuros is laying the groundwork for long-term success. Early progress has been promising, and the team continues to focus on targeted surgeon and distributor engagement, training, and brand awareness through an omnichannel strategy that includes key scientific meetings and driving social media presence. Global Expansion Accelerates – Following recent approval of MagnetOs Granules, ANVISA has now approved MagnetOs Putty for use in Brazil, further expanding Kuros' commercial presence in the growing South American spine market and building on recent global clearances in Lebanon and beyond. First Capital Markets Day Successfully Completed – In May 2025, Kuros hosted its inaugural Capital Markets Day in Zurich, welcoming over 130 attendees in-person and online. The event showcased the company's scientific leadership, global commercial strategy, and clinically proven differentiated approach to bone healing – featuring insights from a leading U.S. foot and ankle surgeon on how bone graft choice directly impacts patient outcomes and day-to-day quality of life. In addition, the Group presented the progress made in transforming its business from a functional, structural and digital perspective. New U.S. Headquarters and Production Facility Construction Underway – As part of its U.S. operational expansion strategy, Kuros has secured a location in Atlanta for a new office and manufacturing facility. The site is expected to support diversified manufacturing and enable Kuros to scale operations and engagement in line with accelerating demand for MagnetOs, with an immersive experience for surgeons, partners, and investors—highlighting the science, innovation, and clinical impact of MagnetOs in an engaging environment. Net operating costs Cost of goods sold amounted to USD 7.1 million in H1 2025 (H1 2024: USD 3.9 million) of which USD 0.9 million (H1 2024: USD 0.9 million) relate to the amortization of capitalized R&D. Net operating costs from continuing operations amounted to USD 52.8 million in H1 2025, compared to USD 32.0 million in the prior year period. Sales and marketing costs increased from USD 20.7 million in H1 2024 to USD 37.4 million in H1 2025, primarily driven by an expanded sales force and higher sales and distribution expenses, in line with the Group's continued commercial expansion. The increase also reflects the initial investments to penetrate the extremities and international markets, supporting future revenue growth and a broader market reach. Research and development costs of continuing operations increased from USD 3.6 million in H1 2024 to USD 4.3 million in H1 2025. This is primarily driven by increased R&D activities, clinical trial expenditures, and higher personnel expenses due to an increase in headcount, reflecting the Group's ongoing commitment to innovation to support long-term growth. General and administrative costs increased from USD 7.8 million in H1 2024 to USD 11.1 million in H1 2025. The increase was mainly driven by the scaling up of back-office functions and building the digital infrastructure to support business growth. Operating profit/ (loss) and group net result The operating profit from continuing operations amounted to USD 3.5 million (H1 2024: operating loss from continuing operations of USD (0.2) million). After accounting for the net finance result, income tax and the profit/loss from discontinued operations, the Group reported a net loss of USD (2.0) million in H1 2025 (H1 2024: USD (0.2) million). Financial position and other assets Cash and cash equivalents amounted to USD 18.4 million as of H1 2025 (December 31, 2024: USD 19.8 million). The decrease in cash balance compared to year-end 2024 is mainly attributable to ongoing investments in growth initiatives and working capital to support rising demand. Funds available (including trade and other receivables) for financing the operations of Kuros amounted to USD 45.3 million as of H1 2025. This is an increase of USD 7.8 million from USD 37.5 million as of December 31, 2024. As of H1 2025, total intangible assets amounted to USD 17.6 million (2024: USD 16.4 million) and goodwill amounted to USD 24.2 million (2024: USD 21.3 million). Outlook Kuros expects MagnetOs to continue its strong growth trajectory in the spine and extremity segments, gaining further market share in the U.S., Europe and the rest of the world, and launching in additional countries. The company remains sufficiently financed to support its planned organic growth path and continues to expect robust sales growth of at least 60% in 2025. Based on the solid performance in the first half of the year, Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction. Key figures H1 2025 H1 2024Restated In TUSD, IFRS Revenue from product sales 63,480 35,684 Cost of goods sold (7,148) (3,896) Gross profit 56,332 31,788 Sales and marketing costs (37,394) (20,723) Research and development costs (4,305) (3,610) General and administrative costs (11,136) (7,826) Other income 6 126 Net operating costs (52,829) (32,033) Operating profit/ (loss) 3,503 (245) Net finance result (3,366) 1,857 Profit before tax 137 1,612 Income taxes (2,173) (1,466) Net (loss)/ profit from continuing operations (2,036) 146 Profit/ (loss) from discontinued operation, net of tax 23 (382) Net loss (2,013) (236) Net loss per share from continuing operations (in USD) (0.05) 0.00 Net loss per share (in USD) (0.05) (0.01) June 30, 2025 Dec 31, 2024Restated Cash and cash equivalents 18,442 19,762 Trade and other receivables 26,886 17,698 Half Year Report 2025The Kuros Biosciences Half Year Report 2025 can be downloaded via the following link on our website: Kuros Biosciences Interim Report 2025 Half Year Results 2025 – WebcastKuros will host a virtual webcast to discuss H1 2025 financial results on August 14, 2025, at 3:00pm CET. Investors can join the webcast via the following link: Investor Webcast RegistrationThe respective presentation can be downloaded via the following link:Kuros Biosciences WebCast H1 2025 Upcoming EventsOctober 16, 2025 – Trading Update Q3 2025 For further information, please contact:Kuros Biosciences AG Alexandre Müller Daniel Geiger Investor Relations Chief Financial Officer Tel +41 43 268 32 31 Tel +41 44 733 47 41 IR@ Growing bone with MagnetOsTM gives surgeons confidence where it matters most – delivering predictable fusion outcomes.2 In a Level I human clinical study published in Spine, MagnetOs achieved nearly twice the fusion rate (79% vs. 47%) of autograft in posterolateral fusions (PLFs).2 Among active smokers – who made up 1 in 5 patients – the fusion difference between MagnetOs and autograft was even more dramatic.**†2,3 MagnetOs grows bone on its own thanks to NeedleGripTM – a proprietary submicron surface technology that harnesses the immune system to stimulate bone growth, without added cells or growth factors.‡§4-9 Ready-to-use, easy to mold, and reliably staying put10, MagnetOs carries no intrinsic risk of human tissue-related disease transmission and is FDA cleared for use throughout the spine, including interbody procedures. ¶6-9 Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions. Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words 'will' or 'expect' or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. * Adjusted EBITDA excludes recurring and one-time share-based compensation and the relevant social security charges** 19 of initial 100 patients were active smokers.† Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.2‡ Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit § MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft. ¶ MagnetOs must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA & mixed with autograft in posterolateral spine & intervertebral disc space. MagnetOs Granules must be hydrated with blood in the intervertebral disc space. Data on file. MagnetOs MIS. Stempels, et al. Spine. 2024;49(19):1323-1331. van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024. van Dijk, et al. eCM. 2021;41:756-73. van Dijk, et al. J Immunol Regen Med. 2023;19:100070. Instructions for Use (IFU) MagnetOs Granules. Instructions for Use (IFU) MagnetOs Putty. Instructions for Use (IFU) MagnetOs Easypack Putty. Instructions for Use (IFU) MagnetOs Flex Matrix. Data on file. MagnetOs Putty and MagnetOs Easypack Putty. Attachment Kuros Biosciences Press Release H1 2025 Results
Yahoo
6 hours ago
- Yahoo
Fed rate-cut drumbeat pegs back dollar; Asian stocks take a breather
By Jaspreet Kalra SINGAPORE (Reuters) -The U.S. dollar was under pressure on Thursday as traders piled into wagers that the Federal Reserve will resume cutting interest rates next month, powering Bitcoin to a record high, while a blistering rally in regional stocks took a breather. MSCI's gauge of equities in Asia excluding Japan nudged higher and lingered near its loftiest level since September 2021, taking cues from Wall Street, where the S&P 500 and Nasdaq indexes hit new closing highs for the second straight day. The MSCI All Country World Index rose to a record high for the second straight session on Wednesday. Japan's Nikkei fell after a searing six-day rally that boosted it past the 43,000 mark for the first time. Shares in Korea and Taiwan were slightly lower as well. China's blue-chip stock index and shares in Hong Kong gained. The dollar fell to a two-week low against a basket of major peers on shifting expectations of U.S. rate cuts, with comments from the U.S. Treasury Secretary also helping bolster expectations of an outsized 50 basis point cut. The Japanese yen hit a three-week high of 146.38 per dollar in early trading. [FRX/] Treasury Secretary Scott Bessent said on Wednesday that an aggressive half-point cut was possible in September after revised labour market data from last week showed that job growth had slowed sharply in May, June and July. Goldman Sachs said on Wednesday in a research note it expects the U.S. Federal Reserve to deliver three 25-basis-point interest rate cuts this year and two more in 2026. Traders are pricing in certainty of a rate cut in September with odds of a 50 bps cut rising to 7%, up from 0% a week earlier. While a tame U.S. inflation report this week boosted the case for rate cuts, some analysts have cautioned against market complacency, saying that upcoming data may alter expectations. "We're not as convinced of a 25bp FOMC rate cut in September as financial markets, let alone a 50bp rate cut," said Carol Kong, economist and currency strategist at Commonwealth Bank of Australia. "There will be another CPI and payrolls report ahead of the September meeting that can make or break the case for a rate cut," Kong said. BITCOIN, GOLD Optimism on monetary policy easing in the world's largest economy also powered cryptocurrency bitcoin to an all-time high of $124,002.49 with analysts also pointing to recent financial sector reforms as a tailwind for the asset class. Bitcoin has risen 32% so far in 2025, and the second largest cryptocurrency, Ethereum, has climbed 41% and is hovering just shy of its all-time high hit in November 2021. In commodity markets, gold prices rose 0.5% to $3,371 and crude oil prices edged up after hitting a two-month low on Wednesday as investors kept their focus on the summit between U.S. President Donald Trump and Russian leader Vladimir Putin on Friday. [O/R] [GOL/] Trump on Wednesday threatened "severe consequences" if Putin did not agree to peace in Ukraine but also said that a meeting between them could swiftly be followed by a second one that would include Ukrainian President Volodymyr Zelenskiy. In the past, Trump has said both sides will have to swap land to end fighting that has cost tens of thousands of lives and displaced millions. "While lack of progress towards a ceasefire may lead to renewed threats of secondary oil tariffs/sanctions, we see limited risk of large disruptions in Russia supply," analysts at Goldman Sachs wrote in a note. Large volumes of Russian exports, the possibility of deepening price discounts to maintain demand, and the likely eagerness of key buyers India, and especially China, to continue energy cooperation with Russia are expected to avert major disruptions, they said. Trump signed an executive order last week levying an additional 25% tariff on India's exports to the U.S., saying that the country directly or indirectly imported Russian oil. He has also hinted at similar tariffs on China.
